Cycle Pharmaceuticals
Dr Alejandra Bruna is a cancer biologist who leads the Preclinical Modelling of Paediatric Cancer Evolution team at the Institute of Cancer Research, London. Dr Bruna leads and contributes to preclinical programmes using improved patient-derived tumour models building towards an integrative and personalised approach to cancer medicine.
Dr Bruna obtained her Ph.D. from the University of Barcelona, followed by two postdoctoral fellowships at Mount Sinai School of Medicine, New York City and Vall d’Hebron Institute, Barcelona.
Dr Bruna coordinated and co-led one of the largest translational research efforts in the academia setting by developing and validating a framework for deep molecular and phenotypically annotated patient-derived tumour xenografts (PDXs) and short-term cultures of PDX cells with Professor Carlos Caldas at the Cancer Research UK Cambridge Institute. Dr Bruna is now expanding her experience and expertise into paediatric cancers by leading a team at the ICR to help achieve kinder and smarter treatments for children with cancer.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Cycle Pharmaceuticals
1 followers
Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering best-in-class drug treatments and services to the under-served rare disease patient community.